5-(2-chloroacetyl)-1-methylindolin-2-one | 118306-97-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-(2-chloroacetyl)-1-methylindolin-2-one
• 英文别名: 5-(2-chloroacetyl)-1-methyl-1,3-dihydroindol-2-one；5-(chloroacetyl)-1-methyl-1,3-dihydro-2H-indol-2-one；5-(2-chloroacetyl)-1-methyl-3H-indol-2-one
• CAS: 118306-97-1
• 化学式: C₁₁H₁₀ClNO₂
• mdl: MFCD07366366
• 分子量: 223.659
• InChiKey: RRFQHTVONYSCEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(2-chloroacetyl)-1-methylindolin-2-one 在 三乙基硅烷 、 三氟乙酸 作用下， 反应 3.08h， 以94%的产率得到5-(2-Chloroethyl)-1-methyl-2,3-dihydro-1H-indol-2-one
  参考文献：
  名称：

  [EN] OXINDOLE SUBSTITUTED PIPERAZINE DERIVATIVES
  [FR] DERIVES DE PIPERAZINE SUBSTITUES PAR UN OXINDOLE

  摘要：

  这项发明涉及公式（I）的化合物，其中Ar，A，R，R1，R2，R3，R4和R5在规范中定义，包含它们的药物组合物以及它们在治疗中枢神经系统疾病中的用途。

  公开号：

  WO2004037820A1
• 作为产物：
  描述：

  氯乙酰氯 以92%的产率得到
  参考文献：
  名称：

  LOWE, JOHN A. (III);NAGEL, ARTHUR A.

  摘要：

  DOI：

文献信息

• Oxindole substituted piperazine derivatives
  申请人：——

  公开号：US20040142933A1

  公开（公告）日：2004-07-22

  This invention relates to compounds of the formula I 1 wherein Ar, A, R, R 1 , R 2 , R 3 , R 4 and R 5 are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.

  本发明涉及公式I1的化合物，其中Ar、A、R、R1、R2、R3、R4和R5的定义如规范中所述，包含它们的药物组合物以及它们在治疗中枢神经系统疾病中的应用。
• METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER
  申请人：Romano Steven Joseph

  公开号：US20080269246A1

  公开（公告）日：2008-10-30

  The present invention, in one aspect, relates to a method of using piperazinyl-heterocyclic compounds of the formula I, as defined below, for enhancing cognition in a mammal, including a human, for example a mammal afflicted with psychosis, autism, dementia, or mental retardation, comprising administering an effective amount of a compound of formula I (for example, ziprasidone) to the mammal. In another aspect, the present invention is directed to a method for reducing or ameliorating in a mammal, including a human, afflicted with a disorder or condition selected from autism, mental retardation, obsessive-compulsive disorder, and dementia, positive symptoms (e.g. excessive aggression, disinhibited sexual behavior, inappropriate sexual behavior, agitation, compulsive behavior such as head banging, lip biting, self mutilation, or stereotypic behavior) associated with the aforementioned disorders or conditions, which method comprises administering an effective amount of a compound of formula I (for example, ziprasidone) to the mammal. In another aspect, the present invention is directed to a method for treating pediatric bipolar disorder in a mammal, including a human, which method comprises administering an effective amount of a compound of formula I (for example, ziprasidone) to the mammal. The compounds of the formula I are defined as follows: or a pharmaceutically acceptable acid addition salt thereof, wherein Ar, n, X, and Y are as defined.

  本发明在某些方面涉及使用公式I所定义的哌嗪基-杂环化合物的方法，以增强哺乳动物（包括人类）的认知能力，例如患有精神病、自闭症、痴呆或智力低下的哺乳动物，包括给哺乳动物（例如齐拉西酮）的公式I化合物的有效剂量。在另一个方面，本发明涉及一种方法，用于减轻或改善患有自闭症、智力低下、强迫症和痴呆症等疾病或症状的哺乳动物（包括人类）的阳性症状（例如过度攻击、解禁性行为、不当性行为、焦虑、强迫行为，如头撞击、咬唇、自残或刻板行为），该方法包括向哺乳动物（例如齐拉西酮）的有效剂量的公式I化合物的管理。在另一个方面，本发明涉及一种用于治疗哺乳动物（包括人类）的儿童双相情感障碍的方法，该方法包括向哺乳动物（例如齐拉西酮）的有效剂量的公式I化合物的管理。公式I化合物定义如下：或其药学上可接受的酸盐，其中Ar，n，X和Y如定义。
• Piperazinyl-heterocyclic compounds
  申请人：PFIZER INC.

  公开号：EP0281309B1

  公开（公告）日：1991-12-27
• Irreversible Nek2 Kinase Inhibitors with Cellular Activity
  作者：Jeffrey C. Henise、Jack Taunton

  DOI：10.1021/jm200222m

  日期：2011.6.23

  A structure-based approach was used to design irreversible, cysteine-targeted inhibitors of the human centrosomal kinase, Nek2. Potent inhibition of Nek2 kinase activity in biochemical and cell-based assays required a noncatalytic cysteine residue (Cys22), located near the glycine-rich loop in a subset of human kinases. Elaboration of an oxindole scaffold led to our most selective compound, oxindole propynamide 16 (JH295). Propynamide 16 irreversibly inhibited cellular Nek2 without affecting the mitotic kinases, Cdk1, Aurora B, or Plk1. Moreover, 16 did not perturb bipolar spindle assembly or the spindle assembly checkpoint. To our knowledge, 16 is the first small molecule shown to inactivate Nek2 kinase activity in cells.
• Medicament for the treatment of glaucoma and ischemic retinopathy
  申请人：Pfizer Products Inc.

  公开号：EP0985414B1

  公开（公告）日：2003-08-27